| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | A− | 82 | Hyper-growth (EPS +128.8% YoY) with exceptional PEG ratio (0.42), 52.7% 52-week return, low beta (0.45) providing defensive positioning | 6–12M |
| SA Quality/Value Composite | B+ | 77 | Revenue growth 47.4% YoY; PE 54.4x elevated but forward PE 28.5x reasonable for growth rate; dividend yield 0.59% provides modest income | 3–6M |
| Zacks Earnings Momentum | A | 88 | EPS growth 128.83% YoY vs. revenue 47.44% indicates strong operational leverage; PEG ratio of 0.42 signals growth trading at deep discount to valuation multiples | 1–3M |
| Institutional & Smart Money Flow | B | 74 | Market cap $1.12T ranks top-tier pharma; 52-week range $623–$1,249 reflects volatility; avg volume 2.94M shares shows adequate liquidity for institutional deployment | 6–12M |
| Growth Sustainability & Moat | A− | 81 | Pharma sector positioning; hyper-growth flag active; low beta (0.45) suggests structural competitive advantage and pricing power; revenue growth 47.4% YoY sustainable in specialty pharma | 6–12M |
| Valuation & Safety (Pre-Penalty) | B | 72 | High valuation flag active (PE 54.4x); forward PE 28.5x more reasonable; PEG 0.42 indicates undervaluation on growth basis; EV $1.12T large-cap cushion | 3–6M |
| Penalty Overlay | −8pts | — | High valuation flag (−3pts); strong profitability flag absent (−4pts); no earnings date available (−1pt) limits earnings catalyst visibility | Near-term |
| CONFIDENCE SCORE | A | 86 | Core metrics (PE, EPS, growth, beta, market cap) all present and reliable; dividend data available; limited visibility on TTM revenue and earnings date does not materially degrade conviction | 6–12M |
| Volatility & Drawdown Risk | B+ | 76 | Beta 0.45 indicates 45% of market volatility; 52-week drawdown from $1,249 to $623 (50%) shows sector-specific pressure risk; current positioning near 52-week highs | 3–12M |
| Crowding Risk Flag | ELEVATED | 61 | 52.7% 52-week return signals momentum crowding; hyper-growth flag active; $1.12T market cap attracts passive/ETF flows; defensive beta (0.45) may limit further upside surprise | 3–6M |
Eli Lilly operates in the Pharmaceuticals sector, competing against giants (JNJ, MRK, AZN, AMGN) on innovation, pipeline depth, and pricing power. LLY's 128.8% EPS growth significantly outpaces sector median (~8–15%), driven by specialty drug portfolio and GLP-1 momentum. The 0.42 PEG ratio is exceptional—typically elite-tier biotech trade at PEG >1.0—indicating either deep undervaluation or unsustainable growth assumptions. Low beta (0.45 vs. sector ~0.8) suggests LLY carries defensive characteristics unusual for hyper-growth names, possibly reflecting institutional quality and dividend stability. Peer multiples (JNJ PE ~26x, MRK PE ~15x) indicate LLY trading at premium justified only if growth trajectory holds through 2027–2028.
Zacks momentum score of 88/100 and +128.8% EPS growth create near-term tailwinds. However, crowding risk is elevated (61/100)—the +52.7% 52-week return suggests retail/momentum accumulation. Absence of disclosed earnings date limits catalyst visibility; upcoming quarterly results will be critical inflection point. Valuation penalty (−8pts) reflects stretched trailing PE (54.4x), though forward PE (28.5x) offers relief. Risk: mean reversion if guidance disappoints; upside limited by crowding and defensive beta.
Growth sustainability score (81/100) and PEG ratio (0.42) support conviction that LLY's earnings expansion is genuine, not speculative. Pharmaceutical sector tailwinds (aging populations, GLP-1 adoption, specialty pricing) justify 47.4% revenue growth. Low beta (0.45) provides downside cushion in market corrections. However, valuation normalization risk remains if competitive pressure intensifies or pipeline delays emerge. Confidence score (86/100) reflects strong data availability and metric reliability, mitigating tail-risk surprises. Dividend (0.59% yield) offers modest return buffer for patient capital.
LLY Analyst Price Target Forecast - ESEN Analytics
LLY analyst price target: $1270 average (range $850-$1600), based on 29 Wall Street analysts.
ESEN AI Commentary: Analysts diverge sharply on whether LLY's recent earnings beat represents sustainable acceleration or pulls forward demand from future periods—the $750 range between lowest and highest targets reflects disagreement on Mounjaro and Zepbound penetration curves, with bulls factoring multi-year volume growth at premium pricing and bears modeling margin compression from competition and pricing pressure in obesity drugs by 2027.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
Generated: 2026-09-29T23:04:26Z
> build_news_intel failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfYZqWFhCMUnmxej8PEjS'}
Generated: 2026-09-29T23:04:31Z
> build_fundamental_earnings failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CfYZqpc19hXJvy5VDu62x'}
LLY Systematic Research
Eli Lilly demonstrates exceptional fundamental momentum, with systematic screening highlighting a 47.44% year-over-year revenue expansion and 128.83% EPS growth—performance metrics substantially outpacing traditional pharmaceutical peers. The company's ROE of 101.31% ranks among the highest in large-cap healthcare, reflecting extraordinary capital efficiency despite the elevated P/B ratio of 38.29 that signals premium market expectations embedded in the valuation.
Profitability metrics reveal structural advantages across the income statement. The gross margin of 82.83% and net margin of 34.99% indicate pricing power and operational leverage, likely driven by recent portfolio additions in diabetes and obesity therapeutics. The beta of 0.51 positions LLY as a defensive holding with lower volatility than broader equity markets, while the current price of $1,148.84 trades approximately 8% below the 52-week high of $1,249.45.
Key strengths include:
- Triple-digit earnings growth substantially exceeding revenue expansion, demonstrating margin improvement
- Return on assets of 22.73% reflecting efficient deployment of the asset base
- Current ratio of 1.58 providing adequate near-term liquidity coverage
Risk factors center on valuation sustainability, with the P/E ratio of 42.57 and P/S multiple of 14.89 demanding continued execution on growth initiatives. The debt-to-equity ratio of 1.6 reflects moderate leverage that requires monitoring during patent cliff transitions.
Relative to Johnson & Johnson, Merck, and Pfizer, the model indicates LLY commands premium multiples justified by superior growth rates, though this positioning creates elevated sensitivity to clinical trial outcomes and competitive therapeutic developments.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.